Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
12:47pm, Monday, 21'st Aug 2023
Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
01:19pm, Friday, 18'th Aug 2023
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks presents investors with the better value op
3 Strong Biotech Performers To Watch As Sector Nears Breakout
07:16am, Thursday, 17'th Aug 2023
The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.
Here's Why Exelixis (EXEL) is a Strong Value Stock
03:26pm, Tuesday, 15'th Aug 2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock
01:47pm, Friday, 11'th Aug 2023
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Biotech Stocks You'll Regret Not Buying Soon
11:37pm, Tuesday, 08'th Aug 2023
The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist ( VC ) companies increased investments from 2,200 in 2016 to 3,100 in
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
01:27pm, Wednesday, 02'nd Aug 2023
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Exelixis, Inc. (EXEL) Q2 2023 Earnings Call Transcript
10:20pm, Tuesday, 01'st Aug 2023
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Mo
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
07:25pm, Tuesday, 01'st Aug 2023
Exelixis (EXEL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.22 per share a year ago.
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
09:08am, Saturday, 29'th Jul 2023
As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new
7 Best Cancer Stocks to Invest in Now
07:00am, Friday, 28'th Jul 2023
One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which hav
EXEL or RGEN: Which Is the Better Value Stock Right Now?
01:08pm, Tuesday, 25'th Jul 2023
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors wi
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
08:08am, Thursday, 20'th Jul 2023
The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand that one o
Exelixis: Stock Likely To Break Out Of 5-Year Inertia
02:00am, Tuesday, 18'th Jul 2023
Exelixis, an oncology-focused company, has reported a sixth consecutive profitable year in 2022, with about 30% revenue growth due to increased sales of its drug, cabozantinib. EXEL reported total rev
3 No-Brainer Stocks to Buy With $200 Right Now
05:21am, Wednesday, 21'st Jun 2023
Every correction and bear market in the major stock indexes has marked an ideal buying opportunity for long-term investors. These three phenomenal businesses have the perfect blend of competitive adva
